Clinical Trials Logo
  1. Home
  2. Melanoma
  3. NCT02352428
  4. Details
NCT02352428 Clinical Trial

Skin Cancer Screening Education Study

Melanoma Clinical Trial

— SCSES  

Official title:
Skin Cancer Screening Education Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT02352428
Other study ID # LEO-SCSES_1013
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 2015
Est. completion date September 2019

Study information
Verified date May 2019
Source Association of Dermatological Prevention, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall aim of this population-based screening study is to assess whether the skin cancer screening training of family physicians and dermatologists leads to improved screening outcomes. The training course aims to increase the accuracy of detecting early stages of skin cancer. Screening outcomes of an intervention region (Calgary, Canada) in which physicians receive training will be compared with screening outcomes of a control region (Edmonton, Canada) where no physician training is administered.

The investigators will determine whether:

- clinical screening outcomes are more favorable in the group of trained physicians compared to non trained physicians

- there is an increase of knowledge about skin cancer screening among trained physicians, compared to non trained physicians

- skin cancer screenings are associated with psycho-social harms

- population-based screening has an effect on the overall incidence and stage-specific-incidence of skin cancer in Alberta

The investigators are aiming to recruit 100 physicians per region (total of 200 physicians) who will screen 40,000 to 80,000 individuals over a period of 20 months.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 113
Est. completion date September 2019
Est. primary completion date December 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria:

1. Screenees

- Male and female residents of Alberta mainly living and receiving care in Edmonton or in Calgary

- Age 20+

- English-speaking

- Individuals who consent to participate

2. Physicians

- Registered dermatologists and family physicians administering care either in Edmonton or in Calgary

- English-speaking

- Physicians who consent to participate

Exclusion Criteria:

Physicians who have undergone special training in skin cancer screening within the last 2 years

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Skin Cancer Screening Training
Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.

Locations
Country Name City State
Canada University of Calgary, University of Alberta Calgary, Edmonton Alberta

Sponsors (3)
Lead Sponsor Collaborator
Association of Dermatological Prevention, Germany University of Alberta, University of Calgary

Country where clinical trial is conducted

Canada, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change in the diagnostic accuracy including knowledge on skin cancer screening Educational outcomes of physicians will be measured pre- and post-training using knowledge tests in the intervention and control region month 1 pre-training (intervention and control region), month 1 post-training (intervention region only), and month 12 (both regions)
Primary Number needed to screen (NNS) to identify 1 skin tumor and number needed to excise (NNE) to identify 1 skin tumor Case report forms will be analyzed to determine clinical screening outcomes such as the NNS, NNE and tumor thickness. 20 months
Primary Patient-rated well-being A patient questionnaire will be used to assess psycho-social harms of skin cancer screenings. 20 months
Primary Trends of overall skin cancer incidence and stage-specific-incidence Up to 6 years (2012-2018)
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study

External Links